Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
3
×
boston blog main
life sciences
national blog main
biotech
boston top stories
cancer
deals
national top stories
new york blog main
san francisco blog main
andrew berens
avapritinib
azacitidine
beta-thalassemia
blueprint medicines
cancer immunotherapy
center for medicare and medicaid services
clinical trials
companion diagnostic
dacogen
daniel o'day
deciphera pharmaceuticals
decitabine
dna
epigenetics
epizyme
farydak
fda
flagship pioneering
foundation medicine
foundationone cdx
foundationone heme
fulcrum therapeutics
gastrointestinal stromal tumor
genentech
gist
gleevec
imatinib
insulated genomic domains
What
morning
3
×
medicine
tumor
acquire
agreed
aims
announced
approach
approval
based
big
billion
biotech
blueprint
broad
called
cancer
chasing
confidence
deadly
debuts
deciphera
developing
didn’t
drug
drugs
epigenetic
epigenetics
fda
field
filing
flagship’s
forms
foundation
gain
genentech
gi
medicines
momentum
new
Language
unset
Current search:
morning
×
boston
×
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
